Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Healthcare | Drugs - Generic | USA
statements
Index- P/E- EPS (ttm)-4.13 Insider Own1.50% Shs Outstand38.56M Perf Week10.15%
Market Cap753.08M Forward P/E- EPS next Y-2.85 Insider Trans0.75% Shs Float36.52M Perf Month17.02%
Income-156.80M PEG- EPS next Q-0.94 Inst Own- Short Float21.65% Perf Quarter46.73%
Sales58.80M P/S12.81 EPS this Y-8.00% Inst Trans5.31% Short Ratio12.93 Perf Half Y67.50%
Book/sh0.19 P/B102.79 EPS next Y27.80% ROA-60.50% Target Price26.67 Perf Year24.00%
Cash/sh4.56 P/C4.28 EPS next 5Y- ROE-271.20% 52W Range8.76 - 19.69 Perf YTD72.53%
Dividend- P/FCF- EPS past 5Y-29.50% ROI-59.30% 52W High-0.81% Beta1.39
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin86.20% 52W Low122.95% ATR0.75
Employees272 Current Ratio6.00 Sales Q/Q211.40% Oper. Margin- RSI (14)81.02 Volatility4.95% 4.36%
OptionableYes Debt/Eq26.57 EPS Q/Q13.10% Profit Margin- Rel Volume1.72 Prev Close18.99
ShortableYes LT Debt/Eq26.57 EarningsNov 07 AMC Payout- Avg Volume611.55K Price19.53
Recom1.70 SMA2014.33% SMA5024.45% SMA20052.29% Volume1,049,086 Change2.84%
Dec-05-19Initiated Craig Hallum Buy
Nov-25-19Initiated BTIG Research Buy $27
May-09-19Upgrade The Benchmark Company Hold → Buy $19
Jan-04-19Reiterated Needham Buy $42 → $36
Jan-04-19Downgrade The Benchmark Company Buy → Hold
Jun-28-18Initiated The Benchmark Company Buy $39
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
Dec-06-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-17-19 07:14AM  Edited Transcript of FLXN earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-11-19 07:30AM  Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings GlobeNewswire
Nov-07-19 07:15PM  Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
Nov-04-19 07:48AM  Before You Buy Flexion Therapeutics, Inc. (NASDAQ:FLXN), Consider Its Volatility Simply Wall St.
Nov-01-19 04:40PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Oct-31-19 04:30PM  Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019 GlobeNewswire
02:20PM  Is Flexion Therapeutics Inc (FLXN) A Good Stock To Buy? Insider Monkey
07:30AM  Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis GlobeNewswire
Oct-24-19 03:57PM  5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger
Oct-14-19 07:00AM  Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA® GlobeNewswire
12:17AM  3 Top Biotech Stocks With Major Catalysts in October TipRanks
Oct-13-19 04:33PM  The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Oct-11-19 08:56AM  Do Options Traders Know Something About Flexion Therapeutics (FLXN) Stock We Don't? Zacks
Oct-04-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:40AM  Health Check: How Prudently Does Flexion Therapeutics (NASDAQ:FLXN) Use Debt? Simply Wall St.
Oct-02-19 09:00AM  Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA) GlobeNewswire
Sep-30-19 09:04AM  Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-23-19 09:00AM  Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S. GlobeNewswire
Sep-18-19 09:31AM  Buy These 7 Small Drugmakers to Boost Your Portfolio's Health Zacks
Sep-10-19 07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga +7.06%
Sep-09-19 04:01PM  Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexions Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain GlobeNewswire
Sep-06-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-04-19 09:55AM  Flexion Therapeutics, Inc. (FLXN) Shares March Higher, Can It Continue? Zacks
08:23AM  Need To Know: Flexion Therapeutics, Inc. (NASDAQ:FLXN) Insiders Have Been Buying Shares Simply Wall St.
Sep-03-19 02:21PM  In expense-laden biotech industry, here are the Mass. startups most in need of cash American City Business Journals
Aug-28-19 04:30PM  Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference GlobeNewswire
Aug-10-19 12:01PM  3 Healthcare Stocks With Rising Expectations Motley Fool
Aug-07-19 05:45PM  Edited Transcript of FLXN earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents +11.71%
04:26PM  Flexion Therapeutics, Inc. (FLXN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 06:35PM  Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Flexion Therapeutics Reports Second-Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
Aug-05-19 08:53AM  How Should Investors Feel About Flexion Therapeutics, Inc.'s (NASDAQ:FLXN) CEO Pay? Simply Wall St.
Aug-02-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -7.16%
Jul-30-19 04:30PM  Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019 GlobeNewswire
10:38AM  Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-15-19 07:30AM  Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Patients with Advanced Knee OA GlobeNewswire +6.12%
Jul-05-19 06:47AM  Flexion Therapeutics, Inc. (NASDAQ:FLXN): When Will It Breakeven? Simply Wall St.
Jul-03-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-24-19 01:28PM  Heres What Hedge Funds Think About Flexion Therapeutics Inc (FLXN) Insider Monkey -6.44%
Jun-20-19 09:00AM  Flexion Therapeutics Named one of Boston Business Journals Best Places to Work for the Third Consecutive Year GlobeNewswire
Jun-18-19 04:30PM  Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-07-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-06-19 02:27PM  Edited Transcript of FLXN earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-05-19 08:30AM  Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis GlobeNewswire
May-30-19 06:58AM  If You Had Bought Flexion Therapeutics (NASDAQ:FLXN) Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today Simply Wall St.
May-20-19 12:48PM  These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month Motley Fool
May-14-19 04:30PM  Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-12-19 09:50PM  Heres What Hedge Funds Think About Flexion Therapeutics Inc (FLXN) Insider Monkey
May-10-19 01:06PM  Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Call Transcript Motley Fool +8.74%
07:30AM  Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
May-09-19 11:58AM  Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today Motley Fool +19.32%
09:45AM  Chevron, Conduent, Flexion, and More: Stocks in the Spotlight Insider Monkey
May-08-19 06:35PM  Flexion Therapeutics (FLXN) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.47%
05:25PM  Flexion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-02-19 09:00AM  Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International (OARSI) World Congress GlobeNewswire
May-01-19 04:30PM  Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-25-19 07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
Apr-24-19 04:30PM  Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Apr-23-19 12:53PM  Flexion Therapeutics, Inc. (NASDAQ:FLXN): Time For A Financial Health Check Simply Wall St.
Apr-05-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-03-19 04:30PM  Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference GlobeNewswire
Apr-02-19 07:30AM  Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal Drugs GlobeNewswire
Apr-01-19 09:00AM  Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board GlobeNewswire
Mar-11-19 08:00AM  Mutual Fund Managers Are Bullish On Stock Market Forecast But Some Are Hedging Bets Investor's Business Daily
Mar-04-19 04:30PM  Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference GlobeNewswire -5.02%
07:00AM  Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors CNW Group
03:18AM  Edited Transcript of FLXN earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 04:45PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.73%
Feb-28-19 08:20PM  Flexion Therapeutics Inc (FLXN) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results GlobeNewswire
Feb-26-19 04:30PM  Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference GlobeNewswire
Feb-21-19 04:30PM  Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage GlobeNewswire
10:31AM  Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-20-19 04:30PM  Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Feb-12-19 09:46AM  Opening Bell, February 12, 2019 CNBC Videos
Feb-11-19 04:05PM  Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy GlobeNewswire
11:41AM  Here's Why Flexion Therapeutics Rose 29.8% in January Motley Fool
Feb-08-19 09:00AM  Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12 GlobeNewswire
Feb-01-19 05:00PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.74%
Jan-30-19 07:20AM  Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-22-19 04:30PM  Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer GlobeNewswire -5.14%
Jan-04-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.41%
07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga
Jan-03-19 04:36PM  Flexion shares plummet after weak revenue guidance MarketWatch
04:01PM  Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019 GlobeNewswire
12:05PM  Raymond James: Flexion Therapeutics Estimates Are A Stretch Benzinga
10:26AM  Flexion Starts Phase III Enrollment on Zilretta for Hip OA Zacks
Jan-02-19 04:30PM  Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study GlobeNewswire +10.07%
Dec-20-18 04:00PM  Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019 GlobeNewswire
Dec-17-18 04:30PM  Flexion Therapeutics Submits Supplemental New Drug Application (sNDA) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Dec-11-18 11:01AM  Here's Why Flexion Therapeutics Jumped 20.5% in November Motley Fool
Dec-04-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-18 10:07AM  2 Small Biotech Stocks That Insiders Are Buying TheStreet.com
Nov-27-18 01:53PM  Flexion Therapeutics Inc (NASDAQ:FLXN): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
08:45AM  New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAHAFFY PATRICK JDirectorAug 29Option Exercise0.1630,8244,93230,824Aug 29 04:46 PM
Willwerth ChristinaChief Strategy OfficerAug 13Option Exercise0.168,7501,40067,169Aug 14 04:06 PM
Clayman Michael D.President and CEOAug 08Buy10.852,31725,13672,249Aug 08 04:38 PM
COLELLA SAMUEL DDirectorAug 08Buy10.742,00021,48045,333Aug 09 04:05 PM
Arkowitz DavidChief Financial OfficerMay 31Buy11.052,50027,62789,424Jun 03 04:18 PM
MERRIFIELD C ANNDirectorMay 23Buy12.648,000101,12010,000May 24 09:15 AM
Arkowitz DavidChief Financial OfficerMay 13Buy11.994,00047,96086,924May 15 04:05 PM
Clayman Michael D.President and CEOMay 10Buy12.484,01250,06774,868May 13 09:15 AM
Arkowitz DavidChief Financial OfficerMay 08Sale10.062,24822,61582,924May 09 04:32 PM
Clayman Michael D.President and CEOMar 12Buy12.364,04650,00970,856Mar 13 04:11 PM
Levine Mark S.General CounselJan 03Sale12.367349,0729,060Jan 04 05:12 PM
Wentworth KerryChief Regulatory OfficerJan 03Sale12.366227,68811,207Jan 04 05:10 PM
KELLEY SCOTTChief Medical OfficerJan 03Sale12.366227,68815,271Jan 04 05:09 PM
Bodick NeilChief Scientific OfficerJan 03Sale12.367469,22164,782Jan 04 05:06 PM
Clayman Michael D.President and CEOJan 03Sale12.363,27840,51666,810Jan 04 05:03 PM
open in yahoo | open in reuters | open in google